AU675935B2 - Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy - Google Patents

Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy Download PDF

Info

Publication number
AU675935B2
AU675935B2 AU39589/93A AU3958993A AU675935B2 AU 675935 B2 AU675935 B2 AU 675935B2 AU 39589/93 A AU39589/93 A AU 39589/93A AU 3958993 A AU3958993 A AU 3958993A AU 675935 B2 AU675935 B2 AU 675935B2
Authority
AU
Australia
Prior art keywords
tetrazol
biphenyl
antagonist
international
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39589/93A
Other languages
English (en)
Other versions
AU3958993A (en
Inventor
Norman Eugene Cameron
Frank Carey
Mary Anne Cotter
Alexander Anthony Oldham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929208116A external-priority patent/GB9208116D0/en
Priority claimed from GB929211289A external-priority patent/GB9211289D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AU3958993A publication Critical patent/AU3958993A/en
Application granted granted Critical
Publication of AU675935B2 publication Critical patent/AU675935B2/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Alteration of Name(s) in Register under S187 Assignors: ZENECA LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU39589/93A 1992-04-13 1993-04-07 Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy Ceased AU675935B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929208116A GB9208116D0 (en) 1992-04-13 1992-04-13 Therapeutic agents
GB9208116 1992-04-13
GB9211289 1992-05-28
GB929211289A GB9211289D0 (en) 1992-05-28 1992-05-28 Heterocyclic therapeutic agents
PCT/GB1993/000732 WO1993020816A1 (en) 1992-04-13 1993-04-07 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy

Publications (2)

Publication Number Publication Date
AU3958993A AU3958993A (en) 1993-11-18
AU675935B2 true AU675935B2 (en) 1997-02-27

Family

ID=26300705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39589/93A Ceased AU675935B2 (en) 1992-04-13 1993-04-07 Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy

Country Status (14)

Country Link
EP (2) EP0636027B1 (enExample)
JP (1) JPH07505646A (enExample)
KR (1) KR100292396B1 (enExample)
AT (1) ATE181830T1 (enExample)
AU (1) AU675935B2 (enExample)
CA (1) CA2132544C (enExample)
DE (1) DE69325574T2 (enExample)
DK (1) DK0636027T3 (enExample)
ES (1) ES2135472T3 (enExample)
GR (1) GR3031261T3 (enExample)
HU (1) HUT71331A (enExample)
NO (1) NO313935B1 (enExample)
NZ (1) NZ251741A (enExample)
WO (1) WO1993020816A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232663C (en) * 1995-10-06 2008-04-08 Novartis Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
AU1791497A (en) 1996-02-29 1997-09-16 Novartis Ag At1 receptor antagonist for the stimulation of apoptosis
SK283348B6 (sk) * 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CZ297795B6 (cs) 1998-12-23 2007-03-28 Novartis Ag Tablety obsahující valsartan
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
EP2650011A1 (en) 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
CN102885818B (zh) 2006-03-20 2016-05-04 诺华股份有限公司 治疗或预防炎性痛的方法
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN107744519A (zh) 2010-01-19 2018-03-02 诺华股份有限公司 改良神经传导速度的方法和组合物
KR20250007040A (ko) 2017-07-07 2025-01-13 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234854A (en) * 1989-08-11 1993-02-25 Ici Plc Quinoline derivatives, preparation, intermediates and pharmaceutical compositions thereof
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
EP0528762B1 (de) * 1991-08-15 1997-05-07 Novartis AG N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten

Also Published As

Publication number Publication date
AU3958993A (en) 1993-11-18
ES2135472T3 (es) 1999-11-01
ATE181830T1 (de) 1999-07-15
DE69325574T2 (de) 2000-03-16
KR100292396B1 (enExample) 2001-09-17
WO1993020816A1 (en) 1993-10-28
CA2132544C (en) 2005-10-18
NO943846L (no) 1994-10-12
EP0872235A1 (en) 1998-10-21
DK0636027T3 (da) 2000-01-31
NZ251741A (en) 1997-06-24
NO943846D0 (no) 1994-10-12
GR3031261T3 (en) 1999-12-31
HUT71331A (en) 1995-11-28
EP0636027A1 (en) 1995-02-01
DE69325574D1 (de) 1999-08-12
CA2132544A1 (en) 1993-10-28
NO313935B1 (no) 2002-12-30
HU9402932D0 (en) 1995-02-28
JPH07505646A (ja) 1995-06-22
EP0636027B1 (en) 1999-07-07

Similar Documents

Publication Publication Date Title
AU675935B2 (en) Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy
Nair Final report on the safety assessment of polyvinylpyrrolidone (PVP)
AU674501B2 (en) Compositions containing histamine-H2-receptor antagonists at low dosage
DE69432595T2 (de) Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen
EP0302008A2 (en) 5HT-3 antagonists for prevention of dependence
Miller Pharmacokinetics and bioavailability of ranitidine in humans
JPH05194227A (ja) 薬 剤
Castell et al. Nephrogenic diabetes insipidus due to demethylchlortetracycline hydrochloride
HUE027280T2 (en) Angiotensin II Receptor Antagonists to Treat High Blood Pressure in Cats
EP0561977B1 (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
DE102005031577A1 (de) Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
JPH08511253A (ja) アンギオテンシン変換酵素阻害剤とａ▲ｉｉ▼アンタゴニストとの組み合わせ
EP0346445A1 (en) Dextrorphan potentiator for anticonvulsant composition and method
DE69132782T2 (de) Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie
US6448280B1 (en) Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
EP1123703A1 (en) Immunomodulatory drug composition
Chappell et al. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine
Stengel et al. Fluconazole versus ketoconazole in the treatment of dermatophytoses and cutaneous candidiasis.
DE602004005000T2 (de) Methode zur behandlung von niereninsuffizienz
JP2554819B2 (ja) 不安の治療における共力剤および薬剤組成物
Lawson et al. Amoxycillin: Pharmacokinetic studies in normal subjects, patients with pernicious anaemia and those with renal failure
Moore et al. Effect of beta-adrenergic blockade on plasma-renin activity and intractable hypertension in patients receiving regular dialysis treatment
US5189037A (en) Synergistic combinations in the treatment of anxiety
JP2007091661A (ja) 外用抗真菌剤組成物
DE69923982T2 (de) Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER WAS: ZENECA LIMITED